Pre-Clinical Testing
CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose of 100mg BID Continued high response rate with favorable safety and tolerability profile observed in heavily pre-treated patients at 100mg BID Encouraging durable responses and progression free survival at 100mg BID Excerpt from the Press Release: CAMBRIDGE, Mass., Dec. 16, 2021…
Read More
Data from preclinical studies in collaboration with Fred Hutchinson Cancer Research Center will be presented at ASH and provide strong rationale for use of EOS-448 as a single agent and in combination with an immunomodulatory drug in patients with multiple myeloma Preclinical data shared at TIGIT Therapies Digital Summit highlight evidence for multifaceted mechanism of…
Read More
Preclinical pseudovirus data and structural modeling shows ABP 310 retains activity and potency against the SARS-CoV-2 Omicron variant mutations ABP 310 EUA possible as early as 2022 Excerpt from the Press Release: WOBURN, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) — Abpro Corporation, a clinical stage biotechnology company developing next-generation antibody therapies, today shared an assessment of…
Read More
Funding provides $16 million in support for Ontario cancer research Excerpt from the Press Release: December 2, 2021—Toronto—Today the Ontario Institute for Cancer Research (OICR) announced funding for 16 studies as part of the Institute’s new Clinical Translation Pathway (CTP). These awards support pre-clinical research and new clinical trials that have a focus on early…
Read More
Responses to immune checkpoint inhibitors improved after adding radiation therapy. Date:November 18, 2021 Source:Massachusetts General Hospital Summary:Immune checkpoint inhibitors strengthen the immune response against cancer cells, but the medications are ineffective against certain tumors. Results from a new clinical trial indicate that adding radiation may overcome this resistance to immune checkpoint inhibitors. Excerpt from the…
Read More
Excerpt from the Press Release: COVID-19 vaccination is safe for pregnant women and not associated with higher rates of complications, data released by the UK Health Security Agency showed on Thursday, as officials urged pregnant women to take up the offer of shots. The real-world data from the rollout of COVID-19 vaccines in Britain support other studies around the…
Read More
Excerpt from the Press Release: Data Reported at the 2021 Society for Immunotherapy of Cancer Annual Meeting SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today reported in vitro and in vivo preclinical…
Read More
Data support ability of AU-007, a computationally evolved, human IgG1 monoclonal antibody, to specifically block IL-2’s binding to CD25 and inhibit tumor growth in multiple cancer models Data show potential of novel cancer treatment to break negative feedback loop caused by IL-2 and prevent Treg expansion Excerpt from the Press Release: LARKSPUR, Calif.–(BUSINESS WIRE)–Aulos Bioscience,…
Read More
—Selective targeting of IL-2, a potent immunomodulator, to CD8+ T cells results in enhanced anti-tumor activity across multiple in vivo animal models and an enhanced safety profile — — IND filing for AB248 on-track for 3Q 2022 — Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Asher Biotherapeutics, a biotechnology company developing precisely-directed immunotherapies…
Read More
ALPHA2 Study Abstract Selected for Oral Presentation Highlights the Benefits of Consolidation Dosing with ALLO-501A in Patients with Relapsed/Refractory Large B Cell Lymphoma ALPHA Study Abstract Selected for Poster Presentation Continues to Show Durability of Responses to ALLO-501 in Patients with Non-Hodgkin Lymphoma UNIVERSAL Study Abstract Selected for Oral Presentation Reports Meaningful Activity of a…
Read More